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Abstract 
Background: Studies report conflicting evidence regarding the existence of a DCIS-associated premalignant path-
way in BRCA mutation carriers. We aimed to examine the prevalence, phenotype, and expression of oncodrivers in 
pure DCIS (pDCIS) and invasive breast cancer with concurrent DCIS (IBC + DCIS) in mutation carriers.
Methods: A cohort of BRCA1 and BRCA2 mutation carriers >18 years old who underwent surgery for breast cancer 
at an academic hospital (1992–2011) and had pathology available for review were included for study. Invasive breast 
cancer (IBC) and DCIS were stained for ER, PR, HER1, HER2, and HER3, and C-MET. DCIS prevalence was evaluated. 
Correlation of IBC and DCIS phenotypes was evaluated in patients with IBC + DCIS. DCIS and IBC expression of tumor 
markers were examined by BRCA mutation.
Results: We identified 114 breast tumors. Of all BRCA1-associated tumors, 21.1 % were pDCIS and 63.4 % were 
IBC + DCIS. Of all BRCA2-associated tumors, 23.3 % were pDCIS and 60.5 % were IBC + DCIS. In BRCA1 and BRCA2 
mutation carriers with IBC + DCIS, there was a significant correlation in ER, PR, and HER3 expression between the DCIS 
and IBC components. Most BRCA1-associated DCIS did not express ER, PR or HER2, while most BRCA2-associated DCIS 
did express ER and PR. BRCA1− as well as BRCA2-associated DCIS had expression of HER3 and C-MET.
Conclusions: The majority of BRCA-associated tumors had DCIS present. Concordance of DCIS and IBC phenotypes 
was high, arguing for the existence of a DCIS-associated premalignant pathway. Oncodrivers HER3 and C-MET were 
expressed in the DCIS of mutation carriers, suggesting an opportunity for prevention strategies.
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Background
For individuals who carry a germline mutation in either 
the BRCA1 or BRCA2 gene, risk of developing breast 
and/or ovarian cancer is much greater than among the 
general population [1, 2]. However, mutation carri-
ers only account for 7–10 % of breast cancers cases and 
10–15  % of ovarian cancers cases [3–7]. Several studies 
have shown that the morphological and immunohisto-
chemical phenotypes of BRCA1- and BRCA2-related 
breast cancers differ from that of sporadic breast can-
cers [8–10]. Compared to sporadic breast cancers, both 
BRCA1- and BRCA2-related breast cancers are more 
likely to be high grade and poorly differentiated [11–14]. 
It has been shown that BRCA1-related breast cancers 
have low expression of estrogen receptor (ER), proges-
terone receptor (PR) and human epidermal growth fac-
tor receptor (HER2/neu) as compared with sporadic 
breast cancers [15]. However, the ER and PR expression 
of BRCA2-related breast cancers does not seem to differ 
from that of sporadic cancers [16].
Much is known about the phenotypic differences 
between BRCA-associated and sporadic breast can-
cers, yet little is known about the differences in their 
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pre-invasive progression pathways. Because more BRCA-
related breast cancers are discovered between screening 
mammograms and with no prior pathologic findings [17, 
18], it has previously been thought that the DCIS-asso-
ciated premalignant pathway that exists among sporadic 
breast cancers is not present within the BRCA-associated 
disease spectrum. Studies have reported that DCIS is less 
often found near BRCA1- and BRCA2-associated inva-
sive tumors when compared to sporadic tumors [19, 20]. 
However, more recent studies have found that high-risk 
pre-invasive lesions such as DCIS are more frequently 
found in prophylactic mastectomy specimens of BRCA 
mutation carriers than in control mammoplasty speci-
mens [21–24].
Within the general population, DCIS has become a 
target for therapies aimed to prevent the development 
of invasive breast cancer. The relatively long period of 
latency between the onset of DCIS and development of 
sporadic invasive breast cancer has offered an opportu-
nity to develop neoadjuvant interventions. Several neo-
adjuvant trials are underway for patients with DCIS, 
including anti-estrogen therapies and vaccines target-
ing HER2, both which have shown promise for patients 
with DCIS [25–27]. This hints at the possibility for new 
prevention options for patients with phenotypes under-
served by currently available therapies, such as BRCA 
mutation carriers.
Today, the prevention of breast cancer among BRCA1 
and BRCA2 mutation carriers has focused on surgical 
options such as risk-reducing bilateral mastectomy and 
bilateral salpingo-oophorectomy. Fortunately, these strat-
egies have been shown to dramatically decrease the risk 
of breast cancer development [28, 29]. Nonetheless, there 
exist significant long-term consequences as well as effects 
on quality-of-life as a result of these surgical prevention 
strategies [30]. For this reason, efforts have been made 
to identify non-surgical prevention techniques for this 
patient population. Importantly, there is evidence that 
tamoxifen decreases risk of primary breast cancer as well 
as contralateral breast cancer for BRCA1 and BRCA2 
mutation carriers [31, 32]. While studies are underway 
investigating additional options for chemoprevention in 
mutation carriers, there currently exist a paucity of non-
surgical prevention strategies for this high-risk patient 
population.
Due to the substantial risk of breast cancer conferred 
by the BRCA1 and BRCA2 mutations, development of 
prevention strategies for mutation carriers is imperative. 
Chemoprevention strategies have been developed for 
the general population based on the known phenotypes 
of spontaneous DCIS and breast cancer, suggesting the 
importance of evaluating the phenotypes of hereditary 
breast tumors in order to develop targeted therapies. A 
growing body of literature supports targeting the HER 
family for prevention of ER-negative and possibly ER-
positive breast tumors [33]. As such, investigating the 
phenotypes of BRCA-associated DCIS, specifically the 
HER tumor antigens, could elucidate possible targets to 
exploit in DCIS as a means of preventing invasive tumors 
in mutation carriers.
In this study we first aimed to identify the prevalence 
of pure DCIS and DCIS associated with invasive tumors 
among BRCA mutation carriers. We then aimed to 
assess the correlation between the phenotypes of inva-
sive tumors and their corresponding DCIS in order to 
evaluate the role of DCIS in BRCA-associated tumor 
progression. Finally, we aimed to determine the unique 
immunophenotypes of BRCA1- and BRCA2-associated 
DCIS to investigate oncodriver expression that may be 
applicable to future prevention strategies.
Methods
Study population
After receiving approval from the Institutional Review 
Board at the University of Pennsylvania (protocol 
#814211), we obtained a list of patients seen in the High 
Risk Screening Clinic who were found to have a BRCA1 
or BRCA2 mutation and were enlisted in the database for 
research purposes. We then restricted to mutation carri-
ers who underwent a mastectomy or lumpectomy at our 
institution during the years of 1992–2011. We excluded 
all patients before 1992, because this was the year that the 
electronic pathology record system was first introduced 
at our institution. We then included only those patients 
who had pathology specimens available for review and 
who had specimens with sufficient tissue available for 
staining purposes (Fig. 1).
Pathology review and staining
All breast cancer specimens were reviewed with a surgi-
cal pathologist for presence of DCIS and for tumor char-
acteristics, including morphology of DCIS, distance of 
the DCIS from invasive tumor, and invasive and in  situ 
nuclear grade.
All available pathology blocks for both invasive 
tumor and DCIS were cut and stained for estrogen 
receptor (ER), progesterone receptor (PR), human 
epidermal growth factor receptor 1 (HER1), human epi-
dermal growth factor receptor 2 (HER2), human epider-
mal growth factor receptor 3 (HER3), and hepatocyte 
growth factor receptor (C-MET). In patients who had 
both invasive tumor and concurrent DCIS, we stained 
both the DCIS and the invasive components. All stains 
were interpreted by a single surgical pathologist. Both 
the percentage of positively stained nuclei and the inten-
sity of staining (0–3) was recorded. An H-score was 
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calculated for HER1, HER3, and C-MET by multiplying 
the percentage of positive nuclei by the stain intensity. 
Patients for whom one or more of the stains were unsuc-
cessful or not interpretable were excluded from the study.
Statistical methods
We examined patient characteristics by BRCA status 
using a Chi square test or t test, as appropriate. Associa-
tions between DCIS characteristics and DCIS prevalence, 
including pure DCIS and invasive breast cancer-asso-
ciated  DCIS, and mutation status were assessed by the 
Chi square test. In patients with invasive breast cancer 
with concurrent DCIS, Pearson correlation coefficients 
were calculated to determine correlation between HER1, 
HER2, and C-MET score in DCIS and invasive tumor, 
while a linear trend test was used to determine correlation 
between ER, PR, and HER2 intensity in DCIS and inva-
sive tumor. Magnitude of DCIS and invasive tumor HER1, 
HER3 and C-MET score were compared by mutation 
status using the Student’s t test, while the Wilcoxon rank 
sum test was used to compare ER, PR and HER2 intensity.
Data management was performed using SAS Version 
9.2 (SAS Institute Inc. 2009, Cary, NC, USA) and statisti-
cal analyses were performed using SPSS Version 21 (IBM 
Corp) or Stata/SE Version 11.1 (StataCorp, College Sta-
tion, TX, USA). A p-value of <0.05 was considered sig-
nificant for all statistical analyses.
Results
We identified 114 breast tumors, of which 71 (62.3  %) 
were BRCA1-associated and 43 (37.7  %) were BRCA2-
associated. Of all IBC, 80.2 % had concurrent DCIS. Of 
all BRCA1-associated tumors, 11 (15.5  %) were pure 
invasive tumors, 15 (21.1  %) were pure DCIS, and 45 
(63.4 %) were invasive tumors with concurrent DCIS. Of 
all BRCA2-associated tumors, 7 (16.3 %) were pure inva-
sive tumors, 10 (23.3 %) were pure DCIS, and 26 (60.5 %) 
were invasive tumors with concurrent DCIS. Prevalence 
of these three tumor types did not differ by mutation sta-
tus (p = 0.95).
When we examined the DCIS in tumors that had both 
invasive and in situ components, we found that the char-
acteristics of the DCIS did not differ by mutation status 
(Table 1). For the majority of BRCA1- and BRCA2-asso-
ciated tumors, the percentage of DCIS was less than 50 %, 
the DCIS morphology was comedo or cribriform, and the 
DCIS grade was high. For both BRCA1- and BRCA2-
associated tumors, the majority of DCIS was intermixed 
with the invasive tumor or just on the periphery (<2 mm 
from the invasive tumor) (Fig. 2).
When examining tumors that had both invasion and 
concurrent DCIS, we found the correlation between 
the invasive and in situ components to be high for most 
immunophenotypes. In BRCA1 mutation carriers with 
IBC + DCIS, the correlation between the DCIS and IBC 
(Tables  2, 3) was highly significant for ER, PR, HER1, 
HER3 (Fig. 3), and C-MET (Fig. 4). In BRCA2 mutation 
carriers with IBC +  DCIS, the correlation between the 
DCIS and IBC was highly significant for ER, PR, HER2, 
and HER3.
Most BRCA1-associated DCIS and IBC had 0/3 stain-
ing intensity for ER, PR and HER2, while most BRCA2-
associated DCIS and IBC had 3/3 staining intensity for 
ER and PR (Tables  4, 5). DCIS expression of ER, PR, 
and HER2 intensity was significantly higher in BRCA-2 
tumors compared to BRCA-1 tumors (Table  4). IBC 
BRCA1/2  
Mutation Carriers,  
High Risk Screening 
Clinic Database <2013, 
N=597 
Excluded patients who had surgery <1992 or 
at OSH,  
or pathology not available for review 
N = 459 
Pathology available for review 
N=138 
Specimens unable to be 
stained
N=24 
Specimens with enough 
tissue for staining 
N= 114 
Fig. 1 Criteria for study inclusion. BRCA1 and BRCA2 mutation carriers who were seen in the High Risk Screening Clinic before 2013 and were 
enlisted in the database for research were included for review. Patients who did not have pathology available, who were treated prior to 1992 (the 
year our electronic health record was introduced), or who treated at an outside hospital were excluded from the study. Patients who had tumor 
specimens without adequate tissue for staining were excluded from the study
Page 4 of 8Yang et al. J Transl Med  (2015) 13:335 
expression of ER and PR intensity were significantly 
higher in BRCA-2 tumors compared to BRCA-1 tumors 
(Table 5).
BRCA1-associated DCIS had expression of HER3 
and C-MET (H-Score 99.5 and 101.9, respectively), 
but lower expression of HER1 (H-Score 6.5), (Table  6). 
BRCA-2 associated DCIS also had expression of HER3 
and C-MET (H-Score 84.3 and 124.8, respectively), but 
lower expression of HER1 (H-Score 16.5), (Table  6). 
DCIS expression of HER3, C-MET and HER1 did 
not differ significantly by mutation status. Similarly, 
BRCA1-associated IBC and BRCA2-associated IBC had 
expression of HER3 and C-MET, but lower expression 
of HER1 (Table  7), which did not differ significantly by 
mutation status.
Discussion
In sporadic breast cancers the molecular profile of DCIS 
and the genetic progression pathway from in situ to inva-
sive cancer have been well characterized [34–40]. The 
aims of the current study were to determine the preva-
lence of DCIS, investigate the unique immunopheno-
types of DCIS, and assess the relationship between the 
phenotypes of invasive tumors and their in situ counter-
parts, among BRCA mutation carriers. By means of this 
investigation we aimed to better understand BRCA-asso-
ciated DCIS and its role in the hereditary tumor progres-
sion pathway.
We were able to analyze the pathology from 104 BRCA-
associated breast tumors. As expected, only 23 tumors 
were pure in situ lesions, while the remainder were inva-
sive tumors with or without concurrent DCIS. Over 80 % 
of all invasive tumors had concurrent DCIS. This is a rel-
atively high rate of DCIS among BRCA-associated inva-
sive tumors, compared with reports from prior studies 
that range from 20 to 56 % [41, 42]. Studies of sporadic 
invasive breast tumors have found rates of concurrent 
DCIS ranging from 56 to 71 % [20, 41]. Our study sug-
gests that DCIS occurs within hereditary invasive tumors 
at a rate similar to that of sporadic tumors, further sup-
porting the hypothesis that DCIS is a precursor to inva-
sive carcinoma in BRCA mutation carriers. Additionally, 
our finding that most of the DCIS was high-grade sug-
gests that the entrance point for BRCA-associated DCIS 
in the tumor progression pathway may be at the high-
grade stage, unlike the progression pathway of sporadic 
Table 1 Characteristics of  DCIS found in  BRCA mutation 
carriers with invasive tumors and concurrent DCIS
BRCA1 BRCA2 P-value
N (%) N (%)
% DCIS 0.14
 <15 % 15 (53.6 %) 8 (32.0 %)
 15–49 % 9 (32.1 %) 8 (32.0 %)
 50+% 4 (14.3 %) 9 (36.0 %)
DCIS morphology 0.10
 Solid 4 (11.4 %) 3 (10.7 %)
 Cribriform 9 (25.7 %) 14 (50.0 %)
 Comedo 19 (52.3 %) 7 (25.0 %)
 Complex 3 (8.6 %) 4 (14.3 %)
DCIS Distance from IBC 0.31
 Intermixed 12 (42.9 %) 14 (56.0 %)
 Peripheral (<2 mm from IBC) 14 (50.0 %) 11 (44.0 %)
 Distant (>2 mm from IBC) 2 (7.1 %) 0 (0 %)
DCIS Grade 0.63
 Low 2 (5.7 %) 1 (3.6 %)
 Intermediate 11 (31.4 %) 12 (42.9 %)
 High 22 (68.9 %) 15 (53.6 %)
Fig. 2 Appearance of tumors with both invasive and in situ components. The majority of DCIS was located on the periphery of the invasive tumor 
(<2 mm from invasion) or intermixed with it, not distant from the invasive tumor
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breast tumors which is thought to begin with low-grade 
in situ disease [40, 43].
We found that among patients with invasive cancer with 
concurrent DCIS, the concordance of expression between 
the DCIS and invasive tumor was remarkably high for 
most biomarkers. Additionally, the majority of DCIS was 
found intermixed with the invasive tumor or in close 
proximity of it. These findings further support the exist-
ence of a DCIS-associated premalignant pathway among 
patients with BRCA mutations. Studies of sporadic breast 
tumors have similarly shown that the molecular profile 
and immunophenotype of DCIS usually parallels that of 
its invasive counterpart [38–40], supporting the popu-
lar believe that sporadic tumors progress through DCIS 
before developing into invasive tumors.
We found that most BRCA1-associated invasive and 
in  situ tumors were triple negative, while most BRCA2-
associated tumors expressed ER and PR but did not express 
HER2. Prior studies have similarly shown that BRCA1-asso-
ciated tumors tend to be ER, PR and HER2 negative, while 
BRCA2-associated tumors are more often ER and PR posi-
tive [15, 16]. Our finding that ER, PR, and HER2 expression 
in mutation carriers mimics what has been demonstrated 
in many other studies, serves to validate and strengthen 
the other results of this current study. However, while most 
BRCA1-associated tumors were triple negative, still a sub-
stantial number of BRCA1-associated DCIS had expres-
sion of ER (20.8 %) or PR (20.8 %), which supports previous 
studies that have demonstrated the benefit of anti-estrogen 
therapy and oophorectomy in BRCA1 patients [28, 29, 32].
Table 2 Correlation of IBC and DCIS expression of ER, PR, and HER2 in mutation carriers with IBC with concurrent DCIS, 
stratified by BRCA mutation
* Linear trend test for a table with ordered rows and columns
IBC ER intensity BRCA1 BRCA2
DCIS ER intensity DCIS ER intensity
0 1 2 3 P value* 0 1 2 3 P value*
0 23 0 2 1 <0.001 4 1 0 0 <0.001
1 1 0 0 0 0 0 0 0
2 0 0 1 3 0 0 4 3
3 0 0 0 2 0 0 1 8
IBC PR intensity DCIS PR intensity DCIS PR intensity
0 1 2 3 P value* 0 1 2 3 P value*
0 23 0 3 2 <0.001 5 0 0 0 0.003
1 0 0 0 0 0 0 1 1
2 0 0 0 1 0 0 2 2
3 0 0 0 4 0 1 1 1
IBC HER2 intensity DCIS HER2 intensity DCIS HER2 intensity
0 1 2 3 P value* 0 1 2 3 P value*
16 5 0 0 0.46 7 5 0 0 <0.001
6 4 0 0 1 6 0 0
2 1 0 0 0 1 0 0
0 0 0 0 0 0 0 2
Table 3 Correlation of IBC and DCIS expression of HER1, HER3, and C-MET in mutation carriers with IBC with concurrent 
DCIS, stratified by BRCA mutation
BRCA1 BRCA2
Pearson Correlation, r N P value Pearson Correlation, r N P value
HER1 score 0.43 42 0.005 −0.09 23 0.69
HER3 score 0.87 25 <0.001 0.95 19 <0.001
C-MET score 0.47 29 0.01 0.34 17 0.19
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Few investigators have examined other oncodriver 
expression in DCIS of mutation carriers, and thus our 
study evaluating HER1, HER3, and C-MET adds to the 
current body of literature regarding immunopheno-
types of hereditary breast cancer. We found that DCIS 
expressed HER3 and C-MET for both BRCA1 and 
BRCA2 mutation carriers. This finding begs the consid-
eration of how to implement strategies to target these 
oncodriver signaling pathways in BRCA mutation carri-
ers so to prevent DCIS and invasive tumors. As the cur-
rent treatment options for mutation carriers with DCIS 
are quite limited, there is undoubtedly a need for the 
development of new techniques geared to halt the devel-
opment of DCIS in this patient population. Given the 
results of our study, possible options for such an effort 
might include the development of vaccines to target 
HER3 and C-MET oncodriver signaling pathways, or the 
utilization of kinase inhibitors for prevention. Nonethe-
less, it is clear that BRCA mutation carriers are a unique 
patient population deserving further investigation, par-
ticularly in regards to prevention strategies that might 
one  day be utilized to prevent the development of pre-
invasive or invasive tumors.
There are several limitations to the present study. First, 
while our study was able to directly assess the prevalence 
and immunophenotypes of DCIS in patients with known 
BRCA mutations, our dataset did not include patients 
Fig. 3 BRCA1 tumor with high correlation of DCIS expression of HER3 
and adjacent invasive tumor expression of HER3
Fig. 4 BRCA1 tumor with high correlation of DCIS expression of 
CMET and adjacent invasive tumor expression of CMET
Table 4 Comparison of  DCIS expression of  ER, PR, 
and HER2 between BRCA1- and BRCA2-associated tumors
BRCA1 BRCA2 Wilcoxon rank 
sum P value
ER intensity <0.001
 0 32 7
 1 1 1
 2 4 6
 3 7 14
PR intensity 0.001
 0 31 9
 1 2 1
 2 4 6
 3 7 13
HER2 intensity 0.04
 0 31 14
 1 14 14
 2 1 1
 3 0 2
Table 5 Comparison of IBC expression of ER, PR, and HER2 
between BRCA1- and BRCA2-associated tumors
BRCA1 BRCA2 Wilcoxon rank 
sum P value
ER intensity <0.001
 0 38 8
 1 1 0
 2 4 7
 3 2 11
PR intensity <0.001
 0 40 10
 1 0 1
 2 1 5
 3 4 10
HER2 intensity 0.56
 0 33 19
 1 13 7
 2 3 2
 3 0 2
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with sporadic breast tumors for comparison. As such, 
we could only speculate how the characteristics of DCIS 
among our patients might compare to that of non-muta-
tion carriers examined in other studies. Secondly, women 
with BRCA mutations are a small patient population and 
thus the number of subjects available for study inclusion 
was quite limited. Furthermore, some of our patients 
were excluded from the study because their pathology 
was no longer available for review or the slides that were 
available did not have sufficient tissue for all stains to be 
completed. While we do not have any reason to believe 
that this group of excluded patients was inherently dif-
ferent from the group maintained for study inclusion, we 
cannot be certain that there was no skewing of our data 
as a result of those patients lost.
Conclusions
In conclusion, we found that the majority of BRCA-asso-
ciated tumors had DCIS present. Among tumors with 
both invasive and in  situ components, the concordance 
of DCIS and IBC phenotypes was remarkably high, argu-
ing for the existence of a DCIS-associated premalignant 
pathway. HER3 and C-MET were expressed in the DCIS 
of mutation carriers, suggesting an opportunity to target 
these oncodriver pathways as a means to prevent DCIS 
and invasive breast cancer. We hope future efforts will 
aim at investigating and implementing DCIS prevention 
strategies in mutation carriers.
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